Page last updated: 2024-10-25

citalopram and Cardiotoxicity

citalopram has been researched along with Cardiotoxicity in 2 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.

Research Excerpts

ExcerptRelevanceReference
"Citalopram treatment was associated with a larger increase in QTc interval than placebo (difference in week 3 QTc adjusting for baseline QTc: 18."2.79Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Spragg, D; Weintraub, D; Yesavage, J, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Faraj, P1
Størset, E1
Hole, K1
Smith, G1
Molden, E1
Dietrichs, ES1
Drye, LT1
Spragg, D1
Devanand, DP1
Frangakis, C1
Marano, C1
Meinert, CL1
Mintzer, JE1
Munro, CA1
Pelton, G1
Pollock, BG1
Porsteinsson, AP1
Rabins, PV1
Rosenberg, PB1
Schneider, LS1
Shade, DM1
Weintraub, D1
Yesavage, J1
Lyketsos, CG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease[NCT00898807]Phase 3186 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cohen-Mansfield Agitation Inventory (CMAI)

CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Citalopram and Psychosocial Intervention27.7
Placebo and Psychosocial Intervention28.7

Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)

"Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from marked improvement(1), no change(4), and marked worsening(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7." (NCT00898807)
Timeframe: Baseline to 9 weeks

Interventionpercentage moderate/marked improvement (Number)
Citalopram and Psychosocial Intervention40
Placebo and Psychosocial Intervention26

NeuroBehavior Rating Scale-- Agitation

NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms. (NCT00898807)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Citalopram and Psychosocial Intervention4.33
Placebo and Psychosocial Intervention5.26

Neuropsychiatric Inventory (NPI)-- Agitation Subscore

NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Citalopram and Psychosocial Intervention7.8
Placebo and Psychosocial Intervention8.0

Trials

1 trial available for citalopram and Cardiotoxicity

ArticleYear
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Cardiotoxicity

2014

Other Studies

1 other study available for citalopram and Cardiotoxicity

ArticleYear
Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients - a study based on a cohort of 19,742 patients.
    EBioMedicine, 2023, Volume: 95

    Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Cardiotoxicity; Child; Citalopram; Es

2023